Source: Scientific Reports. Unidade: ICB
Subjects: IMUNOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, CÉLULAS EPITELIAIS, MELANOMA, FIBROBLASTOS, IMUNIDADE, EXPRESSÃO GÊNICA
ABNT
BERZAGHI, Rodrigo et al. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Scientific Reports, v. 7, n. 40585, p. 1-16, 2017Tradução . . Disponível em: https://doi.org/10.1038/srep40585. Acesso em: 01 nov. 2024.APA
Berzaghi, R., Maia, V. S. C., Pereira, F. V., Melo F. M.,, Guedes, M. S., Origassa, C. S. T., et al. (2017). SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. Scientific Reports, 7( 40585), 1-16. doi:10.1038/srep40585NLM
Berzaghi R, Maia VSC, Pereira FV, Melo F. M., Guedes MS, Origassa CST, Scutti JB, Matsuo AL, Câmara NOS, Rodrigues EG, Travassos LR. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression [Internet]. Scientific Reports. 2017 ; 7( 40585): 1-16.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/srep40585Vancouver
Berzaghi R, Maia VSC, Pereira FV, Melo F. M., Guedes MS, Origassa CST, Scutti JB, Matsuo AL, Câmara NOS, Rodrigues EG, Travassos LR. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression [Internet]. Scientific Reports. 2017 ; 7( 40585): 1-16.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/srep40585